Source link : https://www.newshealth.biz/health-news/kids-with-ms-may-have-better-outcomes-when-started-on-high-efficacy-treatment-early/
Starting high-efficacy monoclonal antibody therapy during childhood reduced long-term disability in pediatric-onset multiple sclerosis (MS), registry data suggested. Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late (ages 20-22). High-efficacy therapy was defined as ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri). At ages 23-27, those who […]
Author : News Health
Publish date : 2024-09-20 21:11:29
Copyright for syndicated content belongs to the linked Source.
Categories